Francis Y Lee

Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.

F. Lee, Adhip P N Majumdar, Pralay Majumder, 2009, Cancer letters.

Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.

Punit Marathe, John S Tokarski, Toomas Mitt, 2002, Journal of medicinal chemistry.

Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.

David K Williams, John S Tokarski, J. Tokarski, 2004, Bioorganic & medicinal chemistry letters.

5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.

Henry Wong, Punit Marathe, John S Tokarski, 2007, Bioorganic & medicinal chemistry letters.

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

J. Mestan, B. Druker, M. Heinrich, 2005, Cancer research.

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.

B. Druker, F. Lee, M. Deininger, 2006, Blood.

New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.

Henry Wong, Punit Marathe, John S Tokarski, 2007, Bioorganic & medicinal chemistry letters.

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.

Paul S Mischel, Timothy F Cloughesy, Joseph A Loo, 2009, Cancer research.